{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T19:10:50Z","timestamp":1770664250461,"version":"3.49.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:00:00Z","timestamp":1478563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81270630"],"award-info":[{"award-number":["81270630"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0165948","type":"journal-article","created":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T18:39:30Z","timestamp":1478630370000},"page":"e0165948","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and Safety of Lenalidomide for Treatment of Low-\/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis"],"prefix":"10.1371","volume":"11","author":[{"given":"Xin-yue","family":"Lian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao-qun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin-fang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-ming","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-mei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,11,8]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMp048266","article-title":"Myelodysplastic syndromes-coping with ineffective hematopoiesis","volume":"352","author":"M Cazzola","year":"2005","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.thj.6200335","article-title":"Myelodysplastic syndromes","volume":"5","author":"WK Hofmann","year":"2004","journal-title":"Hematol J"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2011.044602","article-title":"Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)","volume":"96","author":"L Malcovati","year":"2011","journal-title":"Haematologica"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System","volume":"113","author":"H Kantarjian","year":"2008","journal-title":"Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for myelodysplastic syndromes","volume":"120","author":"PL Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.blre.2007.10.003","article-title":"Supportive care, growth factors, and new therapies in myelodysplastic syndromes","volume":"22","author":"E Hellstrom-Lindberg","year":"2008","journal-title":"Blood Rev"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1365-2141.2003.04272.x","article-title":"Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes","volume":"121","author":"AJ Jansen","year":"2003","journal-title":"Br J Haematol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1038\/onc.2009.207","article-title":"5q-myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics","volume":"28","author":"KM Eisenmann","year":"2009","journal-title":"Oncogene"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"V Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"H Quach","year":"2010","journal-title":"Leukemia"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1073\/pnas.0610477104","article-title":"Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5qsyndrome patients","volume":"104","author":"A Pellagatti","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref12","unstructured":"Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of InterventionsVersion5.1.0; updated March 2011. Cochrane Collaboration 2011. Available at http:\/\/www.cochrane-handbook.org<\/ext-link>"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"JP Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"P Fenaux","year":"2011","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2012-03-415661","article-title":"Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome","volume":"120","author":"RS Komrokji","year":"2012","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3324\/haematol.2011.045914","article-title":"Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies","volume":"97","author":"L Ad\u00e8s","year":"2012","journal-title":"Haematologica"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/leu.2012.369","article-title":"Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis","volume":"27","author":"A Kuendgen","year":"2013","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion","volume":"355","author":"A List","year":"2006","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/bjh.12876","article-title":"Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion","volume":"166","author":"J S\u00e1nchez-Garc\u00eda","year":"2014","journal-title":"British Journal of Haematology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3109\/10428194.2012.728702","article-title":"Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program","volume":"54","author":"I Abouyahya","year":"2013","journal-title":"Leukemia & Lymphoma"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3109\/10428194.2013.778406","article-title":"Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy","volume":"54","author":"EN Oliva","year":"2013","journal-title":"Leukemia & Lymphoma"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.clml.2015.08.083","article-title":"Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine","volume":"15","author":"AM Zeidan","year":"2015","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/leu.2015.296","article-title":"Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion","volume":"30","author":"A Toma","year":"2016","journal-title":"Leukemia"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2141.2011.08979.x","article-title":"Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents","volume":"156","author":"D Sibon","year":"2012","journal-title":"British Journal of Haematology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","article-title":"Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1\u2013risk myelodysplastic syndromes with karyotypes other than deletion 5q","volume":"111","author":"A Raza","year":"2008","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12885-015-1444-1","article-title":"Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)","volume":"15","author":"A Butrym","year":"2015","journal-title":"BMC Cancer"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.V124.21.409.409","article-title":"Efficacy and safety of lenalidomide (LEN) versus placebo (PBO) in RBC-transfusion dependent (TD) patients (Pts) with IPSS low\/intermediate (Int-1)-risk myelodysplastic syndromes (MDS) without del(5q) and unresponsive or refractory to erythropoiesis-stimulating agents (ESAs): Results from a randomized phase 3 study (CC-5013-MDS-005)","volume":"124","author":"V Santini","year":"2014","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood.V126.23.1693.1693","article-title":"Use of lenalidomide in del(5Q) MDS. A National aifa (Agenzia Italiana Del Farmaco) registry study","volume":"126","author":"F Arcioni","year":"2015","journal-title":"Blood"},{"key":"ref29","first-page":"585","article-title":"Lenalidomide treatment in 20 patients with myelodysplastic syndrome (MDS)","volume":"98","author":"B Arrizabalaga","year":"2013","journal-title":"Haematologica"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood.V114.22.2764.2764","article-title":"Treatment of lower risk MDS with del 5q with lenalidomide (len): Results of the french ATU program","volume":"114","author":"F Le bras","year":"2009","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00277-009-0846-z","article-title":"Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression","volume":"89","author":"G G\u00f6hring","year":"2010","journal-title":"Ann Hematol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/leu.2013.305","article-title":"Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS","volume":"28","author":"AF List","year":"2014","journal-title":"Leukemia"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.leukres.2012.11.017","article-title":"Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial","volume":"37","author":"DA Revicki","year":"2013","journal-title":"Leuk Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1056\/NEJMoa0912228","article-title":"Persistent malignant stem cells in del(5q) myelodysplasia in remission","volume":"363","author":"R Tehranchi","year":"2010","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/bjh.12354","article-title":"Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations","volume":"162","author":"M Mallo","year":"2013","journal-title":"British Journal of Haematology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2015-04-640128","article-title":"Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion","volume":"127","author":"V Chesnais","year":"2016","journal-title":"Blood"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0165948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T05:42:41Z","timestamp":1601185361000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0165948"}},"subtitle":[],"editor":[{"given":"Maria R.","family":"Baer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,8]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0165948","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,8]]}}}